• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 502138 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414100607 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414100607 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Earnings Look Back: Seattle Genetics Is Up 3.6% Since Reporting Quarterly Results 1 Week Ago (SGEN)

Published on Sat, 05/18/2013 - 09:13
By Mallory Stone

A week ago on May 7th, 2013 Seattle Genetics (NASDAQ:SGEN) reported earnings and analysts, on average, expected a loss of $0.19 on sales of $53.6 million. Seattle Genetics actually reported a loss of $0.14 per share on sales of $57.3 million, beating EPS estimates by $0.05 and beating revenue estimates by $3.8 million. Shares of Seattle Genetics have climbed from $35.41 to $36.70, representing a gain of 3.6% since the company reported earnings 11 days ago.

In the past 52 weeks, shares of Seattle Genetics have traded between a low of $19.00 and a high of $39.00 and closed Thursday at $36.70, which is 93% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 1.0% while the 50-day MA has advanced 2.2%.

Seattle Genetics, Inc. discovers and develops monoclonal antibody-based drugs to treat cancer and related diseases. The Company's technologies increase the potency and efficacy of monoclonal antibodies with specificity for cancer.

Seattle Genetics (NASDAQ:SGEN) defies analysts with a current price ($36.70) 14.4% above its average consensus price target of $31.40. The stock should discover initial support at its 50-day moving average (MA) of $35.58 and subsequent support at its 200-day MA of $28.72.

By Mallory Stone
mstone@fnno.com

Latest News from FNNO

Shares of Susquehanna Bancshares Fall Be...

Susquehanna Bancshares (NASDAQ:SUSQ) traded at a new 52-week low today of $9.37. So fa ...

Watch for Continued Losses in Shares of ...

Shares of Seachange International (NASDAQ:SEAC) traded today at $6.56, breaking its 52- ...

Select Comfort Looks to Continue to Trad...

Select Comfort (NASDAQ:SCSS) traded today at a new 52-week high of $25.70. This new hi ...

Shares of Paramount Gold and Silver Have...

Paramount Gold and Silver (NYSE:PZG) traded today at a new 52-week low of $0.66. Appro ...

Shares of Precision Castparts Have Falle...

Precision Castparts (NYSE:PCP) traded today at a new 52-week low of $215.09. So far to ...

Watch for Continued Losses in Shares of ...

New Gold (AMEX:NGD) traded today at a new 52-week low of $4.20. Approximately 2.3 mill ...

Shares of Micron Technology Have Risen A...

Micron Technology (NASDAQ:MU) traded at a new 52-week high today of $31.37. This new h ...

Watch for Continued Gains in Shares of M...

Monster Worldwide (NASDAQ:MNST) traded at a new 52-week high today of $99.53. Approxim ...